Characterization of the serotonin transporter in lymphocytes and platelets of schizophrenia patients treated with atypical or typical antipsychotics compared to healthy individuals

Addington, 1993, Assessing depression in schizophrenia in the Calgary depression scale, Br. J. Psychiatry, 164, 39, 10.1192/S0007125000292581 Andreasen, 1995, Symptoms, signs and diagnosis of schizophrenia, Lancet, 346, 477, 10.1016/S0140-6736(95)91325-4 Arora, 1983, Effects of chlorpromazine on serotonin uptake in blood platelets, Psychiatry Res., 9, 23, 10.1016/0165-1781(83)90085-9 Arora, 1993, Serotonin2 receptor binding in blood platelets of schizophrenic patients, Psychiatry Res., 47, 111, 10.1016/0165-1781(93)90041-E Ashton, 1992 Barkan, 2004, Biochemical and pharmacological characterization of the serotonin transporter in human peripheral blood lymphocytes, Eur. Neuropsychopharmacol., 14, 237, 10.1016/S0924-977X(03)00107-X Breier, 1987, Neuroleptic responsivity of negative and positive symptoms in schizophrenia, Am. J. Psychiatry, 144, 1549, 10.1176/ajp.144.12.1549 Dean, 1995, [3H]Paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia, J. Neurochem., 64, 1197, 10.1046/j.1471-4159.1995.64031197.x Fernstrom, 1971, Brain serotonin content: increase following ingestion of carbohydrate diet, Science, 174, 1023, 10.1126/science.174.4013.1023 Goff, 1995, A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia, Psychopharmacology (Berl), 117, 417, 10.1007/BF02246213 Golden, 1990, Serotonin and mood disorder, Psychiatr. Ann., 20, 580, 10.3928/0048-5713-19901001-09 Govitrapong, 2000, Platelet 5-HT2A receptors in schizophrenic patients with and without neuroleptic treatment, Psychiatry Res., 96, 41, 10.1016/S0165-1781(00)00191-8 Govitrapong, 2002, Platelet serotonin transporter in schizophrenic patients with and without neuroleptic treatment, Neurochem. Int., 41, 209, 10.1016/S0197-0186(02)00024-4 Grahame-Smith, 1988, Human platelet 5-hydroxytryptamine receptors: binding of [3H]-LSD. Effects of chronic neuroleptic and antidepressant drug administration, Experentia, 44, 142, 10.1007/BF01952198 Hiemke, 2002, Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects, J. Clin. Psychopharmacol., 22, 502, 10.1097/00004714-200210000-00010 Jacobs, 1991, Serotonin and behavior: emphasis on motor control, J. Clin. Psychiatry, 52, 17 Jockers-Scherubl, 2005, Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study, Int. Clin. Psychopharmacol., 20, 27, 10.1097/00004850-200501000-00006 Joyce, 1993, Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics, Neuropsychopharmacology, 8, 315, 10.1038/npp.1993.32 Kane, 1988, Clorazil collaborative study group. Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine, Arch. Gen. Psychiatry, 45, 789, 10.1001/archpsyc.1988.01800330013001 Kay, 1987, The Positive and Negative Syndrome Scale (PANSS) for schizophrenia, Schizophr. Bull., 13, 261, 10.1093/schbul/13.2.261 Laruelle, 1993, Selective abnormalities of prefrontal serotonergic receptors in schizophrenia: a postmortem study, Arch. Gen. Psychiatry, 50, 810, 10.1001/archpsyc.1993.01820220066007 Lauder, 1983, Hormonal and humoral influences on brain development, Psychoeuroendocrinology, 8, 121, 10.1016/0306-4530(83)90053-7 Lauder, 1978, Serotonin as a differentiation signal in early neurogenesis, Dev. Neurosci., 1, 15, 10.1159/000112549 Lingjaerde, 1983, Serotonin uptake and efflux in blood platelets from untreated and neuroleptic-treated schizophrenics, Biol. Psychiatry, 18, 1345 Linnoila, 1983, Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from non-impulsive violent behavior, Life Sci., 33, 2609, 10.1016/0024-3205(83)90344-2 Lowery, 1951, Protein measurements with the folin phenol reagent, J. Biol. Chem., 193, 265, 10.1016/S0021-9258(19)52451-6 Marazziti, 1989, Lack of specificity of reduced platelet imipramine binding in different psychiatric conditions, Psychiatry Res., 30, 21, 10.1016/0165-1781(89)90168-6 Meltzer, 1989, Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin pKi values, J. Pharmacol. Exp. Ther., 251, 238 Matsubara, 1993, Dopamine D1, D2 and serotonin2 receptor occupation by typical and atypical antipsychotic drugs in vivo, J. Pharmacol. Exp. Ther., 265, 498 Meltzer, 1996, The role of serotonin in schizophrenia and the mechanism of action of antipsychotic drugs. Serotonergic mechanisms, 77 Modai, 1979, Serotonin uptake by blood platelets of acute schizophrenic patients, Psychopharmacology, 64, 193, 10.1007/BF00496061 Naylor, 1996, Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine, J. Neural Transm., 103, 749, 10.1007/BF01271234 Peuskens, 1995, Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol, Br. J. Psychiatry, 166, 712, 10.1192/bjp.166.6.712 Pickar, 1992, Clinical and biological response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine, Arch. Gen. Psychiatry, 49, 345, 10.1001/archpsyc.1992.01820050009001 Pincus, 1996, Reviewing DSM-IV, Am. J. Psychiatry, 153, 850, 10.1176/ajp.153.6.850 Plenge, 1991, [3H]Citalopram binding to brain and platelet membranes of human and rat, J. Neurochem., 56, 248, 10.1111/j.1471-4159.1991.tb02588.x Rotman, 1982, Correlation between serotonin uptake and imipramine binding in schizophrenic patients, Prog. Neuro-psychopharmacol. Biol. Psychiatry, 6, 57, 10.1016/S0364-7722(82)80108-2 Silver, 1992, Fluvoxamine improves negative symptoms in treated chronic schizophrenia. An add-on double-blind, placebo-controlled study, Biol. Psychiatry, 31, 698, 10.1016/0006-3223(92)90279-9 Silver, 1998, Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia, J. Clin. Psychopharmacol., 18, 208, 10.1097/00004714-199806000-00005 Silver, 2000, Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study, Int. Clin. Psychopharmacol., 15, 257, 10.1097/00004850-200015050-00002 Soubrie, 1989, Reconciling the role of central serotonin neurons in human and animal behavior, Behav. Brain Res., 9, 319 Spina, 1994, Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients, Int. Clin. Psychopharmacol., 9, 281, 10.1097/00004850-199400940-00007 Stahl, 2000 Stahl, 2003, Describing an atypical antipsychotic: receptor binding and its role in pathophysiology. Primary care companion, J. Clin. Psychiatry, 5, 9 Tarazi, 2000, Olanzapine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain, Neurosci. Lett., 287, 81, 10.1016/S0304-3940(00)01130-7 Tollefson, 1997, Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial, Am. J. Psychiatry, 154, 457, 10.1176/ajp.154.4.457 Warner, 1995, Clinical descriptions and diagnostic guidelines, 111 Weizman, 1987, Platelet [3H]imipramine binding in autism and schizophrenia, Psychopharmacology, 91, 101, 10.1007/BF00690935